Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)The company is expanding its trial protocol to further explore the...

Aphaia Pharma to Participate in a Panel Discussion at the 10th LSX World Congress ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...

Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes ZUG, Switzerland and SAN JUAN, Puerto Rico, April 25, 2023 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous...

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase ZUG, Switzerland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment...

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity ZUG, Switzerland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention...